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Cells, tissues and organs undergo phenotypic changes and deteriorate as they age. Cell growth arrest and hyporesponsiveness to extrinsic
stimuli are all hallmarks of senescent cells. Most such external stimuli received by a cell are processed by two different cell membrane systems:
receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs). GPCRs form the largest gene family in the human genome and they
are involved in most relevant physiological functions. Given the changes observed in the expression and activity of GPCRs during aging, it is
possible that these receptors are directly involved in aging and certain age-related pathologies. On the other hand, both GPCRs and G proteins are
associated with the plasma membrane and since lipid–protein interactions regulate their activity, they can both be considered to be sensitive to the
lipid environment. Changes in membrane lipid composition and structure have been described in aged cells and furthermore, these membrane
changes have been associated with alterations in GPCR mediated signaling in some of the main health disorders in elderly subjects. Although
senescence could be considered a physiologic process, not all aging humans develop the same health disorders. Here, we review the involvement
of GPCRs and their lipid environment in the development of the major human pathologies associated with aging such as cancer,
neurodegenerative disorders and cardiovascular pathologies.
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965R. Alemany et al. / Biochimica et Biophysica Acta 1768 (2007) 964–975Organisms, cells and even proteins are subject to time-
dependent degenerative processes. As such, aging is character-
ized by the accumulation of adverse changes in cells over time,
which augments the risk of disease, and the breakdown of
homeostatic control and death [1]. Moreover, the process of
aging is also manifested as senescence, involving the deteriora-
tion of certain functions at the cell and tissue level as well as that
of the whole organism. Since aging plays an important role in
many biological processes including development, tumorigen-
esis and death, many attempts have been made to understand the
fundamental features underlying aging [2].
Cell growth arrest and hyporesponsiveness to extrinsic stimuli
are hallmarks of senescent cells [3,4]. The influences of the
external stimuli involved are mainly mediated by two different
systems at the level of the cell membrane. One of these involves
receptor tyrosine kinases (RTKs) that bind growth factors and
activate signal cascades through the phosphorylation of tyrosine
residues in the receptor. The other depends on G protein-coupled
receptors (GPCRs) that make up approximately 5% of the genes
in eukaryotic organisms [5,6]. GPCRs constitute the main family
of receptors for neurotransmitters, hormones and neuromodula-
tors. Upon agonist binding, they undergo conformational
changes that result in the activation of heterotrimeric G proteins
and that modulate the activity of effector proteins (e.g. adenylyl
cyclase [AC], phospholipase C [PLC], A2 [PLA2], guanylyl
cyclase [GC] and some ion channels). These effectors regulate
the cytosolic levels of second messengers, which in turn
influence the activity of third messengers and so on. Finally, a
single signaling event may originate short-, medium-, and long-
term responses that regulate a cell's activity and its responses to
environmental conditions through molecular events such as the
regulation of gene expression, cross-talk and other complex
phenomena. After remaining active for a time, GPCRs are
phosphorylated by G-protein receptor kinases (GRK) and other
kinases, extinguishing the receptor's activity [7,8].Table 1
Some human G protein-coupled receptors (GPCRs) involved in aging and certain ag
GPCRs Typical localization
α2-Adrenoceptors (α2A, α2B, α2C) Noradrenergic and cholinergic
Platelets
Smooth muscle (vascular)
Adipocytes
β-Adrenoceptors (β1, β2, β3) Noradrenergic nerve terminals
Cardiac muscle
Smooth muscle (vascular, bron
Adipocytes
Muscarinic ACh receptors (M1, M2, M3, M4, M5) Central nervous system, some
Cardiac muscle
Exocrine cells
Neuropeptide receptors, gastrin-releasing peptide Central and enteric nervous sy
Somatostatin Brain (hypothalamus)
Peripheral tissues (pituitary, pa
adrenal, kidney)
Thyrotropin receptors ThyroidAge-dependent changes can occur at several different levels,
from the ligand–receptor interaction at the cell surface to the
various downstream signaling cascades with which these
receptors interact. GPCRs form the largest gene family in the
human genome and they are involved in most relevant
physiological functions (Table 1). This fact and the changes
observed in the expression and activity of GPCRs during aging
indicate that these receptors may be involved in aging and
associated pathologies [4].
Membrane lipids have recently been shown to influence
GPCR-associated signaling [9,10] and aging [11,12]. Some
specific properties of cell membranes (i.e., fluidity, nonlamellar
phase propensity, surface packing, thickness, surface charge,
etc.) are critical for many membrane events, such as receptor and
G protein localization, activity and sorting of G protein subunits
upon activation, etc. Moreover, the structure and lipid composi-
tion of the membrane regulates the function and localization of
several membrane signaling proteins [10,13–17]. Changes in
membrane lipid composition are frequently accompanied by
alterations in the fluidity, lipid structure, and functionality of the
membrane [18,19]. Accordingly, modifications in the lipid
composition and the physical properties of cell membranes, in
cell signaling and in gene expression have been identified in
different tissues from elderly subjects, including the brain
[18,20–23]. Interestingly, membrane fatty acid composition is
an important determinant of the lifespan of different species [12].
In this context, alterations in membrane lipids can induce
changes in the activity and localization of GPCRs in aged cells.
Therefore, interventions that involve manipulating dietary lipids
and lipid metabolism, including changes in diet or the
administration of cholesterol-modifying agents and antioxi-
dants, show great promise in slowing or possibly averting the
development of some human diseases associated with aging
including some types of cancer, Alzheimer's disease (AD),
hypertension and other cardiovascular disorders [24–32].e-related pathologies
Response to activation
nerve terminals Inhibition of neurotransmitter (Ach, NA) release
Aggregation
Muscular contraction
Inhibition of lipolysis
chiolar)
Stimulation of NA release (β2)
Positive chronotropic and ionotropic effect (β1)
Muscular relaxation (β2)
Stimulation of lipolysis (β3)
presynaptic sites Implication in memory and learning
Stimulation (M1) or inhibition of ACh release (M2, M3)
Negative inotropic and chronotropic effect (M2)
Increase exocrine secretions (M3)
stem Satiety, thermoregulation, stimulation of cell growth
by autocrine feed-back (small cell lung cancer)
Modulation of neurotransmission, motor and
cognitive functions, reduction of amyloid β-levels
ncreas, gut, thyroid, Inhibition of endocrine and exocrine secretions
Stimulation of thyroid hormone release, increase
of number, size and activity of follicular cells
966 R. Alemany et al. / Biochimica et Biophysica Acta 1768 (2007) 964–975Although senescence could be considered a physiological
process, not all aging individuals develop the same health
disorders. Here we shall review the involvement of GPCRs in
the development of major human pathologies in aging, such as
cancer, cardiovascular and neurodegenerative disorders (mainly
AD). We shall focus on the alterations of membrane lipid
composition and structure associated with these pathologies, its
influence on GPCR signaling, and the beneficial effects of some
fatty acid-rich diets on healthy aging.
1. GPCRs and aging in cancers
In general, there is a positive correlation between age and the
incidence of cancer, in particular in breast, lung, prostate, and
colon cancers [33,34]. Cancers originate through defects in the
control of cell proliferation, usually associated with mutations
in proto-oncogenes, tumor suppressors and other signaling
proteins. Obviously, the probability that a cell might bear a
mutation increases with age and indeed, many cancers require
the accumulation of multiple mutations. For instance, p53
induces apoptosis of cells with genetic alterations that cannot be
repaired and mutations in p53 have been observed in about 50%
of all human tumors. However, p53 alone does not induce
uncontrolled cell proliferation, but rather the deficiency in p53
function allows a cell with mutation in genes involved in
proliferation to divide continuously. It is therefore clear that in
most cancers, the probability of developing a tumor increases
with age (Fig. 1) [35]. Nevertheless, it should be noted that
exceptions to this rule do exist, as is the case for pilocytic
astrocytoma (Fig. 1).
With respect to GPCRs and their related proteins, the role
they fulfill in the control of cell proliferation is closely
associated with their involvement in the development of certain
cancers [36–38]. Indeed, changes in the expression and function
of these receptors may result in cellular transformation [39].
Recent studies have demonstrated that GPCRs are implicated in
tumorigenesis and metastasis [40]. Changes in the expression of
GPCRs or mutations in the genes encoding these receptors have
been observed in some cancers, indicating that certain GPCRs
can behave as potent agonist-dependent oncogenes [41,42].Fig. 1. Age-related incidence of cancer. The figure shows an example of the
increase in the rate of a specific cancer with age (meningioma), representing the
usual trend for most cancers, and an example of a cancer whose prevalence
decreases with age (pilocytic astrocytoma). Adapted from Wrensch et al. 2002.One example of a growth-stimulatory role of GPCRs can be
seen in small cell lung carcinoma (SCLC) cells, where
neuropeptides like gastrin-releasing peptide (GRP), galanin,
vasopressin, etc., activate GPCRs [43–45]. SCLC constitutes
approximately 25% of all lung cancers and it is characterized by
a very low 5-year survival rate, despite the initial sensitivity that
it displays to radio- and chemotherapy. In SCLC, neuropeptides
activate GPCRs that are coupled to more than one G protein
family (i.e., Gq/11 and G12/13) [41] thereby stimulating
phospholipase C [46] and ERK [47] activity, which promotes
cell proliferation. Thus, through an autocrine feedback on
GPCRs neuropeptides represent the principal mitogens of
SCLC [44] and indeed, neuropeptide growth factor antagonists
have been developed to treat SCLC [48].
The detection of activating mutations of the human thyro-
tropin (TSH) receptor in some types of thyroid carcinomas
established a causal link between GPCRs and autonomous cell
growth [49]. The human TSH receptor has an exceptionally
broad profile of G protein coupling and it is able to interact with
members of all four G protein families, Gs, Gi, Gq and G12
[50,51]. The cAMP regulatory cascade has also been implicated
in the control of growth and differentiation, whereas calcium
and diacylglycerol (Gq/phospholipase C-β activation) are
thought to stimulate iodination and thyroid hormone synthesis
[52]. In approximately 30% of hyperfuctional thyroid adeno-
mas, GTPase-inhibiting mutations in Gαs are responsible for
the increased cAMP synthesis characteristic of this tumor.
Similarly, mutations in the THS receptor constitutively activate
its ability to stimulate G- and AC-catalyzed cAMP synthesis
[53–55]. Moreover, alterations in the desensitization of GPCRs
in the thyroid gland play a crucial role in thyroid pathologies
[56]. In differentiated thyroid carcinomas (where TSH acts as a
mitogenic agent), changes in the levels of GRK5 are correlated
with a decrease in the desensitization of the TSH receptor that
provokes an increase in cAMP synthesis [57]. Likewise, an
increase in GRK3 expression was detected in hyperfunctional
thyroid nodules (HTNs), suggesting a potential role for this
GRK as a negative feedback regulator for the constitutively
activated cAMP pathway in these structures [56]. Similar
alterations in GPCR and GRK activation and/or expression are
associated with the development of breast cancer [58–61], with
neoplastic transformation in the prostate [62–65] and in human
colon cancer [66]. All these cancers become more prevalent
with age, most probably due to their dependence on the
accumulation of mutations.
Taken together, these results show that mutations in GPCRs,
G proteins, their effectors and GRKs are all involved in the
etiology of several human cancers, particularly those involving
hormone dependence. Hence, it would appear that these
proteins might be relevant pharmacological targets for selective
strategies aimed at antagonizing distinct mitogenic stimuli.
Tumor growth and metastasis are both processes that are
affected by changes in membrane lipid composition and
accordingly, lipid alterations might be involved in the devel-
opment of some types of cancer. In this context, a wide variety
of molecular entities that control cell proliferation and survival
are membrane-associated proteins. Indeed, alterations in the
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membranes from patients with cancer and from cancer cells that
are resistant to chemotherapy [13,67,68]. Interestingly, com-
pounds that modulate the membrane lipid structure (e.g. fatty
acids) influence the cellular localization and activity of
important membrane-associated signal transduction proteins
[10,14,15,69], thereby producing molecular and cellular altera-
tions that affect cell signaling and division [70,71]. Thus, it is
not surprising that the activity of various anticancer drugs is
associated with their ability to alter membrane lipid composi-
tion, thereby affecting membrane lipid structure. Accordingly,
the possibility of using lipids as targets to overcome anticancer
drug resistance has recently been highlighted [67,72].
2. GPCRs and aging in the brain under normal conditions
and in association with neurodegenerative disorders
A variety of age-related alterations in GPCRs have been
observed in neuronal signaling systems [73]. While age-
associated changes appear to be variable and dependent on the
specific brain region, the expression of most GPCRs and G
proteins decreases in the human brain with age [74–77].
Indeed, like most brain neurotransmitter receptors, the density
of β-adrenoceptors decreases with age in the human brain
[78]. This decline is largely associated with the degeneration
of noradrenergic nerve terminals [79] and it is mainly due to
the loss of high-affinity receptors [76]. The human brain
contains all three subtypes of α2-adrenoceptors identified by
molecular cloning (α2A, α2B, and α2C), the α2A-adrenoceptor
being the most abundant in the frontal cortex [75]. The
density of α2A-adrenoceptors and associated regulatory G
proteins has also been shown to decrease with aging in the
human brain [74,75,80]. The concomitant decrease in the
density of α2A- and β-adrenoceptors in the frontal cortex
suggests a relationship between both these GPCRs [76]. Both
adrenoceptors belong to a large family of membrane receptors
that regulates AC activity through Gαs and Gαi proteins [81–
83]. Some studies reveal a decline of various Gα proteins and
their signal transduction cascades within the aging human
brain [75,76,84,85]. This coordinated decrease in the density
of β- and α2A-adrenoceptors indicates the existence of a
relationship between these receptors and their signaling
proteins [76]. Furthermore, the muscarinic acetyl choline
(ACh) receptor (mAChR) system loses its sensitivity to ACh
stimulation both during aging and in AD [73,86,87]. In
contrast to most receptors and signaling proteins, the presence
of other receptors and signaling-related proteins may also
increase with age, as seen for the imidazoline receptors and
monoamine oxidase [88,89]. This would indicate that the loss
of such elements is not unspecific.
AD is currently the commonest cause of senile dementia
among humans over 65, and it is characterized by a
progressive cognitive decline coupled defined by the loss of
memory, cognitive abilities, and even of personality. These
changes are due to the progressive dysfunction and death of
neurons responsible for learning and memory. AD is
characterized by a variety of pathological features, such asthe extracellular senile plaques formed by amyloid β peptides,
the appearance of intracellular neurofibrillary tangles consist-
ing of twisted filaments of hyperphosphorylated tau protein,
the loss of neuronal subpopulations and cholinergic fibers, and
brain atrophy [90–94]. The amyloid β precursor protein
(APP) is a membrane protein and the proteolytic fragments
generated during AD form deposits on the extracellular face of
the cell membrane. It has recently been demonstrated that a
gradual decline in the cellular processing and maturation of
APP is one of the main pathogenic mechanisms for familial
and age-associated AD [95]. GPCRs have recently been
implicated in APP processing. In this context, the somatostatin
receptor has been identified as a modulator that decreases
amyloid β levels by increasing brain neprilysin activity [96], a
rate-limiting peptidase involved in the physiological degrada-
tion of amyloid β in the brain [97]. Thus, reduced neprilysin
activity contributes to amyloid β accumulation and conse-
quently, to AD development. There is evidence that neprilysin
is down-regulated in the hippocampus and cerebral cortex
with aging [98] and from an early stage of AD development
[99–101], supporting the association of neprilysin activity
with the etiology and pathogenesis of AD. Therefore, the up-
regulation of neprilysin through the somatostatin-activated
GPCR signaling pathway may represent a promising target for
AD therapeutic and preventative strategies [102].
Postsynaptic M1 AChRs are found at high density in the
neocortex and hippocampus, where they mediate cholinergic
neurotransmission in a variety of CNS functions including
learning and memory [103]. Of the neurotransmitter patholo-
gies associated with AD, cholinergic dysfunction occurs early
in the disease process [104] and it is thought to underlie much
of the characteristic cognitive and neuropsychiatric symptoms
[105–107]. In addition, the ability of the mAChR to form high
affinity agonist-binding complexes with G proteins was
impaired in AD [108] and phosphoinositide hydrolysis, as
well as phospholipase C and PKC activity was reduced
[109,110]. Recently, the reduction in M1 AChR/G-protein
coupling has been related to the severity of cognitive symptoms
in the neocortex of AD patients. Thus, that impairment of M1
AChR-mediated signaling through uncoupling of its G protein
may be a neurochemical cause of cognitive decline in AD [111].
Potential mechanisms for the loss of GPCR-G protein coupling
in AD may be aberrant phosphorylation or dephosphorylation
of these receptors, which in turn may alter their association with
G proteins and/or the levels or activity of G proteins (e.g., loss
of GTPase activity). Accordingly, both G protein subunit
concentrations and activity are altered in different regions of the
AD brain, thereby modifying GPCR-mediated AC signaling. In
fact, it has been reported that inhibition of AC mediated by Gs
protein but not Gi is disrupted in various brain regions in AD
patients [112–116]. Furthermore, the interactions between the
β1-adrenoceptor and Gs protein are disrupted in the temporal
cortex in AD [117] and β-adrenoceptor-stimulated cAMP
production is reduced in fibroblasts from sporadic AD cases
[118]. Finally, a deficit in cytosolic PKA has been associated
with the accumulation of neurofibrillary changes and amyloid β
deposits in the AD brain [119].
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role in neurodevelopment, changing significantly during periods
of rapid brain growth [120]. Indeed, neural tissue has the highest
lipid content after adipose tissue. The levels of polyunsaturated
(PUFA) and monounsaturated fatty acids (MUFA) in the
cerebral cortex change from early childhood through late
adulthood [121], and some studies suggest that neurocognitive
function may be related to the fatty acid composition of
developing brain [122–124]. Accordingly, alterations in brain
fatty acid composition have been reported in several diseases
associated with neurodegenerative disorders [125]. Neurode-
generation in AD is accompanied by lipid alterations, such as
changes in the phosphocholine-containing lipids in cerebrosp-
inal fluid [126], and in the levels of phospholipids and fatty acid
in blood plasma and brain membranes [127,128]. Furthermore,
several aspects related to the etiology of AD are associated with
alterations of lipid membrane composition and structure. On the
one hand, levels of plasmalogens (the major ethanolamine
glycerophospholipids in the brain) and long-chain ω-3 PUFAs
(e.g., docohexaenoic acid) decrease in brains of AD patients,
which is proposed to provoke membrane bilayer destabilization
contributing in neurodegeneration [129]. This effect may act
cooperatively with the amyloid cascade mechanism, by render-
ing APP. Accordingly, recent results demonstrate that age-
dependent membrane modifications are associated with altera-
tion in the distribution of presenilin-1 and a beta-APP-cleaving
enzyme, very likely affecting APP processing and leading to its
accumulation [95]. On the other hand, some membrane
alterations could in part explain the cognitive deficits reported
in mice with neurodegenerative disorders [130,131], as well as
the impaired neurotransmitter-associated signaling observed in
AD and aging [132,133]. These specific alterations in membrane
lipids have led to studies on the effects of phospholipid and fatty
acid supplementation on the mental status of patients with AD
and in animal models of aging [28,29,134,135]. Diets rich in
carbohydrate [136], particularly those with a high glycemic
index, and those low in essential fatty acids (particularly
ω-3 long-chain PUFAs) increase the risk of developing AD
[137–140]. Likewise, the risk of AD may be increased through
altered lipid metabolism and neuronal membrane lipid composi-
tion that may lead to changes in neurotransmission, antioxidant
defenses, inflammatory responses, cerebral blood flow, and
cognitive function [20,27,31,141,142]. Of particular interest are
the beneficial anti-oxidant and anti-inflammatory effects of
dietary ω-3 PUFAs, which could be a promise for the preven-
tion of AD [27]. Similarly, essential components of the
Mediterranean diet protect against age-related cognitive decline
[143,144], as well as protecting against atherosclerosis in an
animal model of neurodegeneration [145]. Furthermore, there is
evidence that this diet also benefits inflammatory and cardio-
vascular parameters [25].
3. GPCRs and aging in cardiovascular disorders
Adrenergic receptors are important regulators of cardiovas-
cular physiology. The β-adrenergic receptor is activated by both
noradrenaline and adrenaline, and it is a target for manymedications prescribed to the elderly to treat hypertension,
angina, post-myocardial infarction risk, congestive heart failure,
glaucoma, tremor, and arrhythmias [146]. The β-adrenergic
receptor also exhibits age-related change in its activity in the
cardiovascular system.
3.1. In the heart
Human aging is associated with an increase in the activity of
the sympathetic nervous system and plasma catecholamine
levels [147–150]. In this situation, the cardiac adrenoceptors are
exposed to chronic stimulation and hence, desensitization of
cardiac β-adrenoceptors could be expected with age (for a
review see [151]). Numerous studies in animals show that the
cardiac responses mediated by the β-adrenoceptor diminish
with age. Although such changes in the density of the β-
adrenoceptor in the myocardium with age are not consistent
(decrease, increase and no changes have been reported),
impaired coupling of the β-adrenoceptor to the Gs protein
and to the catalytic unit of the adenylyl cyclase (AC) with age
was consistently observed [152,153].
In humans and animals, a decrease in the levels of the
β1-adrenoceptor and Gs protein in the ventricular myocardium
appear to be responsible for the reduction in β-adrenoceptor
activity in aging [154]. In contrast, the increase in Gi protein
levels and the reduction in the activity of the catalytic subunit of
the AC lead to attenuated cyclic AMP formation in aged right
atrial tissue [155]. However, irrespective of the underlying
mechanism, the responses of the aged human heart to
β-adrenoceptor stimulation and to stimulation by other receptors
(i.e., serotonin 5-HT4 receptors and histamine H2 receptors) that
evoke their effects through activation of AC are impaired. The
density of muscarinic receptors also decreased with age in the
human heart, and there was a significant inverse correlation
between muscarinic receptor density and the age of the subjects.
This decrease in receptor density was accompanied by an
impairment in carbachol-induced inhibition of AC and an
attenuation of the indirect negative inotropic effect of carbachol
with aging [156,157].
Taken together, it appears that autonomic receptor systems
are altered in the aging human heart to protect the heart against a
pronounced reduction in β-adrenoceptor responsiveness.
Indeed, β-adrenoceptors and muscarinic receptors are both
desensitized in parallel, thereby leading to an unaltered in vivo
response of β-adrenoceptor stimulation. Furthermore, GRKs
activity does not change [158] and therefore does not contribute
to (or exaggerate) β-adrenoceptor desensitization.
3.2. In the vasculature
Hypertension, orthostatic hypotension, arterial insufficiency,
and atherosclerosis are common disorders in the elderly, with a
significant morbidity and mortality. It is generally understood
that with advancing age, vascular tone shifts towards vasocon-
striction and producing a hypertensive state. This shift is related
to the precipitous decline of vasorelaxation with advanced age,
stimulated by activation of Gαs-linked receptors (β-adrenergic,
Table 2
Fatty acid composition of phospholipids in erythrocyte membranes (mg/100 mg)
Fatty acid
species
Normotensives Hypertensives
Basal Long-term
olive oil
Basal Long-term
olive oil
14:1 2.21±0.26 2.49±0.16 1.84±0.22 2.62±0.14†
16:0 22.93±0.45 24.08±0.86 24.00±0.67 25.76±0.49
16:1 0.81±0.08 0.80±0.07 0.85±0.08 0.93±0.08
18:0 16.88±0.82 14.56±0.63* 16.42±0.29 13.31±0.68†
18:1 17.49±0.42 20.00±1.01* 17.90±0.79 19.30±0.93
18:2 13.25±0.49 12.05±0.60 12.75±0.79 12.43±0.70
18:3 0.73±0.03 0.42±0.03† 0.68±0.06 0.52±0.05*
20:2 2.14±0.17 2.35±0.22 2.22±0.14 2.14±0.12
20:4 16.98±0.44 16.02±0.73 16.81±0.34 15.47±0.62*
22:5 3.47±0.18 3.30±0.21* 3.28±0.24 2.86±0.12
Others 3.12±0.12 3.92±0.16 2.40±0.22 3.85±0.32†
Total SFA 39.99±0.66 38.89±0.89 40.73±0.59 39.3±0.72
Total MUFA 22.91±0.54 25.36±0.42† 21.42±0.66 25.51±0.47†
Total PUFA 37.10±0.57 35.73±0.55† 37.85±0.68 35.18±0.72†
MUFA:SFA 0.57±0.07 0.65±0.06 0.52±0.05 0.65±0.06†
MUFA:PUFA 0.62±0.05 0.71±0.06* 0.57±0.04 0.72±0.06†
PUFA:SFA 0.93±0.04 0.92±0.03 0.93±0.03 0.90±0.04
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA,
polyunsaturated fatty acids. Values are expressed as the mean±SEM (n=28).
*P<0.05, †P<0.01, when compared to the corresponding basal group.
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been focused on age-related changes in GPCR function, and
specifically on the β-adrenergic receptor cascade [159,160].
In vascular smooth muscle cells the generation of the
vasodilatory agent, cAMP, by AC activation is due to agonist
stimulation of GαsPCRs (β-adrenergic, prostanglandin-E2,
adenosine A2, etc.). Activation of PKA by cAMP initiates
vasorelaxation through different pathways, all of which lead to a
lowering of cytosolic Ca2+ [161]. During aging, β-adrenocep-
tor-mediated function and the subsequent generation of cAMP
in the vasculature declines, leading to impaired vasorelaxation.
Because cAMP is also an anti-proliferative agent, this age-
related decrease may be associated with the progress of
atherosclerosis. The accepted explanation for the age-related
lack of β-adrenoceptor function is that GRK and β-arrestin
expression is upregulated, leading to a higher basal phospho-
rylation and desensitization of the receptors [162,163].
Numerous studies demonstrate that Gαs may also undergo
age-related changes that impair its coupling to β-adrenoceptor
after agonist-binding, decreasing the proportion of high affinity
receptors [164,165]. However, the total β-adrenergic receptor
pool [162,166] and the expression of Gαs in the vasculature
remains unchanged with age [162,167–169]. Further studies of
the changes in G protein function with age in vascular tissue are
needed to determine whether changes in Gαs function underlie
the loss of β-adrenoceptor-mediated vasorelaxation. A recent
report has identified a novel regulator of G protein signaling
(RGS)/GTPase activating protein (GAP) that acts on Gαs [170].
One possible explanation for the age-related alterations
associated with Gαs is that RGS/GAP activity is enhanced in
vessels from older animals. Under these conditions, agonist
exposure would leave β-adrenoceptors in a low-affinity state
due to their dissociation from Gαs. Thus, Gαs would not
stimulate AC to produce cAMP, as Gαs signaling would be
quenched due to the high GAP activity of the RGS/GTPase
activating protein.
Alterations in the membrane content of cholesterol or
phospholipid, in the phospholipid distribution, in the molecular
species of particular phospholipid classes, and in the degree of
fatty acid saturation have also been reported in hypertensive
humans [171–173]. Interestingly, alterations in cell membrane
lipid levels are associated with a reduction in the density of
membrane-associated signaling proteins involved in the control
of blood pressure, such as G proteins and PKC in elderly
hypertensive subjects [23]. Therefore, it appears that one way to
regulate GPCR signaling in the elderly would be through
nutritional and pharmacologic interventions aiming at normal-
izing the abnormal lipid composition of the plasma membrane.
The interest in the potential cardiovascular health benefits of
dietary MUFAs has increased in recent years [174–176]. It has
been demonstrated that in hypertensive normocholesterolemic
and hypercholesterolemic subjects, high oleic acid intake (i.e.
olive oil) lowers blood pressure [176]. Moreover, high oleic
acid intake also normalizes certain alterations in erythrocyte
membrane function in hypertensives, such as the distribution of
the erythrocyte Na+–Li+ countertransport [172] and membrane
cholesterol [177–179]. Normalization of these parameters byolive oil is concomitant with a reduction in blood pressure and
strongly related to lipoprotein and membrane lipid modifica-
tions [30,176,180,181]. In addition, oleic acid regulates the
activity of adrenoceptor, G protein and adenylyl cyclase
activities [71], and the GPCR pathway involved in the control
of blood pressure.
In elderly hypertensive subjects, long-termolive oil consump-
tion reduces the cholesterol/phospholipid ratio in erythrocyte
membranes (before olive oil consumption 0.44±0.00 and after
0.38±0.01, P<0.05), normalizing these values to those of
normotensives (0.37±0.01). These decreases in the levels of
cholesterol in membranes after olive oil consumption are
associated with increased membrane fluidity [182]. Accord-
ingly, a reduction in membrane fluidity (high cholesterol) has
been associated with the development of hypertension [183]
and with an age-related impairment of β-adrenergic-mediated
vasorelaxation and Gαs coupling [22,164,184]. Olive oil
consumption also induces significant changes in the levels of
specific fatty acid moieties in phospholipids and cholesterol
esters (Table 2). In both cases, MUFA levels significantly
increase in elderly humans after long-term olive oil consump-
tion, mainly due to a rise in the proportion of oleic acid (C18:1).
This fact was reflected in a significant increase of the MUFA:
SFA (saturated fatty acid) ratio (from 0.57 to 0.65 in the
normotensive group and from 0.52 to 0.65 in the hypertensive
subjects) and of the MUFA:PUFA ratio in membrane
phospholipids (from 0.62 to 0.71 in normotensive subjects
and from 0.57 to 0.72 in hypertensive subjects). In contrast, the
PUFA:SFA ratio did not markedly change under these
circumstances. These changes induce important alterations in
membrane lipid structure because oleic acid favors the
formation of nonlamellar membrane structures in vitro (hexa-
gonal HII phases) [9,185]. The HII-phase propensity is an
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influences the localization and activity of several membrane-
associated proteins (e.g., G proteins and PKC) [10,14,70,71].
Both the type and the quantities of free or esterified fatty acids
and cholesterol influence the membrane fluidity and HII-phase
propensity [9]. In this context, the normotensive effects of olive
oil could originate from the modulation of HII-phase propensity
(induced by changes in membrane lipids) and its influence on
the interaction of G proteins and PKC, in addition to or
alternative to membrane fluidity. Long-term high oleic acid
intake significantly reduces the membrane levels of Gαi1/2,
Gαs, Gβ and PKCα in elderly hypertensive subjects (Fig. 2).
These effects are accompanied by a reduction in blood pressure
(mean systolic and diastolic blood pressure values were 162.4
and 81.0 mm Hg, respectively before and 138.0 and 72.3 mm
Hg after olive oil consumption, P<0.05), suggesting that the
changes observed may in part account for the normotensive
effects of olive oil. Moreover, these results support the hypo-Fig. 2. G protein and PKCα concentrations in erythrocyte membranes of elderly subj
indicates basal values in control (normotensive) subjects; COO, controls after olive
subjects after long-term olive oil consumption. Panels show the levels of Gαs, Gαi1
standard curves with four points (i.e., total protein loaded vs. integrated optical de
Representative immunoblotting bands are also shown. About 36 μg of total protein w
vs. HB.thesis that the lower basal levels of membrane-associated Gαi1/2,
Gαo and PKCα previously found in elderly hypertensive
subjects [23] result from the compensatory adaptation to other
changes that induce hypertension, rather than to the etiology of
this pathology. Oleic acid has been shown to regulate α2-
adrenoceptors and related signaling proteins in 3T3 cells,
whereas the chemically related analogues had no effect [71].
This effect has been related to the structural regulation of the
membrane induced by this fatty acid and it could explain the
effects induced by high olive oil consumption. Moreover, oleic
acid derivatives have been found to exert a normotensive action
in hypertensive animals [186].
4. Conclusions
There is currently strong evidence that the function and
expression of GPCRs and other related signaling proteins are
affected by age. Thus, altered GPCR signaling may be involvedects. The data shown are the mean±SEM of the G protein densities (n=10). CB
oil consumption; HB, basal values in hypertensive subjects; HOO, hypertensive
/2, Gαo, Gβ and PKCα. Quantification was performed by image analysis, using
nsity) of different protein contents loaded on the same gels as described [23].
as loaded for all subjects. *P<0.05; **P<0.01; ***P<0.001, vs. CB; †P<0.01
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consequence of alterations suffered by senescent cells or due to
its participation in the origin or the development of the disease.
Furthermore, it has recently been hypothesized that aging could
be initiated and modified at the plasma membrane, leading to
the proposal that the membrane might act as a gate which
modulates the signals that induce a senescent phenotype [12].
Thus, aging may alter the lipid composition and structure of
biological membranes, which in turn regulate the activity of
membrane proteins involved in cell signaling and important
physiologic functions, such as growth, neurotransmission and
blood pressure. In this context, small heat shock proteins can act
as membrane lipid sensors capable of recognizing membrane
lipid structures and of modulating them [187]. Moreover, the
possibility of reversing the senescent phenotype by simply
restoring the membrane signaling apparatus confirms the
significance of membrane in the aging [4]. From these results,
it might be hypothesized that the age associated decline of
GPCR signaling could be initiated and modified at the
membrane level and consequently, one way to restore the
effects of this process in elderly humans would be to modify
membrane lipid composition and structure. In this sense, fats are
important in human diet and indeed, different types of food
lipids have been associated with both positive and negative
effects on human health. As such, dietary fatty acids, among
others the long-chain ω-3 PUFAs and the MUFA oleic acid
component of the Mediterranean diet (i.e., olive oil), have been
shown to have beneficial effects in important human patholo-
gies linked to age, such as AD, hypertension and related
cardiovascular disorders [29,30,32].
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